German biotech firm Morphosys said this week its ABd Serotec division has licensed seven of its diagnostic HuCAL antibodies to Spanish biomarker company Proteomika for use in its Promonitor diagnostic.

Promonitor is designed to determine circulating levels of different drugs and the immune response they trigger in patients.

It plans to launch kits in the second quarter of this year containing the HuCAL antibodies that can help monitor certain biopharmaceutical therapies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.